MBRX · Moleculin Biotech, Inc.
$0.49
-0.02 (-3.37%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, the Company had an accumulated deficit of $226.5 million since inception and had not yet generated any revenues from operations. Additionally, management anticipates that its cash on hand of $7.3 million as of June 30, 2026, is not sufficient to fund its planned operations for a period of at least one year from when these condensed consolidated financial statements are issued. These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$11.72M
Shares
19.48M
Volume · Oct 2
422.27K
Avg daily vol (3M)
1.27M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.49
Open$0.51
Day$0.47–0.51
52W close$0.39–13.00
Avg vol 30d1.0M
Short int288K · 1.5% float · 1.0d
Short vol31%
Last earningsMay 14, 2025
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
call held May 14, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.5%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−79%
below
Price vs 50-day avg
−32%
below
RSI (14)
35
neutral
MACD trend
Negative
52-week position
1%
near low
Momentum
relative strength
1-month return
−28%
trailing
6-month return
−82%
trailing
YTD return
−85%
this year
Relative strength
−94%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.48% of float · ▲ +61.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 3-yr range
Squeeze score
42
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
130%
annualized · 1-yr
Max drawdown
−97%
past year
ATR
18.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−79%
Bearish
Price vs 50-day avg
−32%
Bearish
RSI (14)
35
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.48% of float · ▲ +61.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 1%
Range high $13
vs 200-day avg -79%
vs 50-day avg -32%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MBRX
this stock
Moleculin Biotech, Inc.
|
$11.72M | -85.3% | — | — | 1.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MBRX | -19.1% | -28.0% | -82.1% | -2.7% | -85.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -18.9% | -27.5% | -94.3% | -3.6% | -98.2% |